Ensysce Biosciences, Inc.
ENSC
$2.11
$0.052.43%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 654.35% | 331.73% | 153.15% | 685.23% | -62.94% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 654.35% | 331.73% | 153.15% | 685.23% | -62.94% |
| Cost of Revenue | 103.06% | 142.07% | 70.31% | -11.71% | -42.37% |
| Gross Profit | 27.88% | -19.57% | -45.49% | 216.80% | 33.63% |
| SG&A Expenses | 0.71% | 2.34% | -25.07% | -11.75% | 4.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.08% | 52.99% | 32.95% | -11.73% | -23.24% |
| Operating Income | 10.48% | -6.76% | -13.33% | 123.81% | 14.76% |
| Income Before Tax | 11.91% | 37.58% | -1.71% | 124.59% | 12.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 11.91% | 37.58% | -1.71% | 124.59% | 12.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -100.00% | -- | -- |
| Net Income | 11.91% | 37.58% | -1.74% | 124.61% | 11.84% |
| EBIT | 10.48% | -6.76% | -13.33% | 123.81% | 14.76% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 76.49% | 83.09% | 82.89% | 107.68% | 77.30% |
| Normalized Basic EPS | 76.49% | 83.09% | 82.88% | 107.68% | 77.22% |
| EPS Diluted | 76.49% | 83.09% | 82.89% | 107.68% | 77.30% |
| Normalized Diluted EPS | 76.49% | 83.09% | 82.88% | 107.68% | 77.22% |
| Average Basic Shares Outstanding | 274.67% | 269.10% | 494.63% | 220.56% | 287.73% |
| Average Diluted Shares Outstanding | 274.67% | 269.10% | 494.63% | 220.56% | 287.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |